Results 161 to 170 of about 10,848 (199)

Venetoclax and Obinutuzumab in Patients With CLL and Coexisting Conditions

New England Journal of Medicine, 2019
BACKGROUND The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known.
Carsten Utoft Niemann, Thomas J Kipps, Stephen Opat   +2 more
exaly   +3 more sources

Acalabrutinib With or Without Obinutuzumab Versus Chlorambucil and Obinutuzumab for Treatment-Naive Chronic Lymphocytic Leukaemia (ELEVATE-TN): A Randomised, Controlled, Phase 3 Trial

Lancet, The, 2020
Summary Background Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or without obinutuzumab against chlorambucil with obinutuzumab in ...
Jeff P Sharman, John M Pagel, Ian W. Flinn   +2 more
exaly   +2 more sources

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

New England Journal of Medicine, 2017
Rituximab-based immunochemotherapy has improved outcomes in patients with follicular lymphoma. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody.
Wolfram Klapper, Elizabeth H Phillips, Stephen Opat   +2 more
exaly   +3 more sources

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis

New England Journal of Medicine
BACKGROUND Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving standard therapy.
Ana Malvar, Bongin Yoo, Jay P Garg
exaly   +4 more sources

Obinutuzumab in Refractory Membranous Nephropathy: A Case Series

Kidney Medicine
Rationale & Objective Membranous nephropathy (MN), recognized as an autoimmune kidney disease, responds well to anti-CD20 monoclonal antibodies. Obinutuzumab, a type Ⅱ humanized anti-CD20 and immunoglobulin G1 Fc-optimized monoclonal antibody, when ...
Jianghua Chen, Pingping Ren, Guangjun Liu   +2 more
exaly   +2 more sources

Obinutuzumab Is Effective for the Treatment of Rituximab-Refractory PLA2R-Associated Membranous Nephropathy

CKJ: Clinical Kidney Journal
Background Clinical experience with obinutuzumab in patients with rituximab-refractory phospholipase A2 receptor (PLA2R)-associated membranous nephropathy remains limited.
Wen-Yan Su, Jian-Yi Li, Jinzhao Men, Shuo Zhong, Yun-Zhao Wang, Yao Zhang, Liang Xu, Jie Gao, Dan Liu, Rong Wang, Jing Sun, Hai-Ping Wang   +11 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy.

Nephrology, Dialysis and Transplantation
BACKGROUND Rituximab has been shown effective in patients with primary membranous nephropathy refractory to glucocorticoids plus cyclophosphamide (GC+CTX) or calcineurin inhibitors (CNIs), but the response rates remain limited.
Ming-Yue Xu, Yifeng Wang, Mei Wu, Rui-Ying Chen, Wen-Qian Zhao, Mingxin Li, Chuan-Ming Hao, Qiong-Hong Xie   +7 more
semanticscholar   +1 more source

MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial.

Blood
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total, 42 patients were
M. Fürstenau, S. Robrecht, C. Schneider, E. Tausch, A. Giza, M. Ritgen, J. Bittenbring, H. Hebart, B. Schöttker, A. L. Illert, U. Graeven, Andrea Stoltefuss, Bernhard Heinrich, Robert Eckert, A. Fink, Janina Stumpf, K. Fischer, O. Al-Sawaf, F. Simon, Fanni Kleinert, J. Weiss, K. Kreuzer, A. Schilhabel, M. Brüggemann, P. Langerbeins, S. Stilgenbauer, B. Eichhorst, M. Hallek, P. Cramer   +28 more
semanticscholar   +1 more source

Obinutuzumab May Be an Effective and Safe Option for Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis Patients after Multitarget Therapy Including Rituximab

American Journal of Nephrology
Introduction: Rituximab has proven effective and safe in pediatric and adult minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) patients with frequently relapsing nephrotic syndrome.
Yu-Xin Lin, Yixuan Pan, Q. Han, Jianhang Xu, Jun-Ni Wang, Xin Lei, Liang-Liang Chen, Yao-Min Wang, Ping-Ping Ren, L. Lan, Jiang-Hua Chen, Fei Han   +11 more
semanticscholar   +1 more source

Obinutuzumab

Reactions Weekly, 2022
  +5 more sources